Key result
The Abbott AxSYM Digoxin II assay demonstrated less susceptibility to digoxin-like immunoreactive factors interference compared to four of six other methods.
Why the study?
Does the Abbott nonpretreatment AxSYM Digoxin II assay improve quantification of digoxin and reduce susceptibility to DLIFs compared to other standard assays in clinical samples?
Observational (n=233)
Yes
Does the Abbott nonpretreatment AxSYM Digoxin II assay improve quantification of digoxin and reduce susceptibility to DLIFs compared to other standard assays in clinical samples?
The Abbott nonpretreatment AxSYM Digoxin II assay provides reliable digoxin quantification with minimal interference from digoxin-like immunoreactive factors compared to several other standard methods.
Answers are grounded in this paper and cite their sources.
May favor Abbott AxSYM Digoxin II to minimize DLIF interference in monitoring; leaves open effects on dosing accuracy and outcomes.
Performance characteristics of the Abbott nonpretreatment AxSYM® Digoxin II assay were evaluated for quantification of digoxin at four independent sites. Correlation of digoxin measurements with the Abbott pretreatment AxSYM®, Baxter Stratus® II, Abbott TDx/TDxFLx II®, Abbott IMx®, Emit® 2000, and Beckman Synchron CX® digoxin assays showed acceptable agreement, as indicated by: slope values >0.84, r >0.90, y-intercepts for all comparisons at or below the assay detection limit, and Sy|x ranging between 7.5% and 15.4% of the average digoxin value. Susceptibility to interference from digoxin-like immunoreactive factors (DLIFs) was examined in 233 samples from renal patients, liver disease patients, cord blood, and third-trimester pregnancies; the AxSYM Digoxin II assay demonstrated the least DLIFs interference. DLIF susceptibility for four of the methods was significantly greater (P <0.05) than in the AxSYM Digoxin II assay; susceptibilities of the Stratus II and Emit 2000 methods were similar to the AxSYM Digoxin II assay.
No takes yet. Share an insight, caveat, or question.
Azzazy et al. (1997) conducted an observational in Patients susceptible to digoxin-like immunoreactive factors (n=233). Abbott AxSYM Digoxin II assay vs. 6 other digoxin assays was evaluated on Susceptibility to interference from digoxin-like immunoreactive factors (DLIFs) (p=<0.05). The Abbott AxSYM Digoxin II assay demonstrated less susceptibility to digoxin-like immunoreactive factors interference compared to four of six other methods.
Synapse has enriched 10 related papers. Consider them for comparative context: